DEEP RESEARCH · INBODY Q2 REVIEW
InBody 2024 Q2 Semiannual Report Review
A quick check of 2024 Q2 revenue, operating profit, and regional/subsidiary trends
0. Bottom line first
InBody's 2024 Q2 revenue increased 23.6% YoY and operating profit increased 8% YoY. Revenue growth was large in China and the U.S., and sales for DBA and the China segment were identified as new highs.
This is a quick semiannual report review written right after work after waiting for Friday. The analysis tool used was https://www.butler.works/.
+23.6% YoY
Revenue growth versus the prior year was confirmed.
+8% YoY
Operating profit also increased YoY, though less than revenue.
China and U.S. growth high
The large revenue increase in China needs additional checking.
1. Revenue and operating profit
Official fact: The original post summarizes 2024 Q2 revenue growth as 23.6% YoY and operating-profit growth as 8% YoY.
Interpretation: Revenue growth rates in China and the U.S. are large. The reason for the particularly large increase in China is something I need to verify rather than just accept from the headline numbers.
2. Items to verify
The disposal of short-term financial products looks fairly large, so I need to check what exactly happened.
3. Subsidiary trends
By subsidiary, sales for DBA and the China segment appear to have reached new highs.
There was nothing unusual in the subsidiary operating-profit trend.
4. Next analysis
Interpretation: I plan to analyze the rest later. For now, the key notes are revenue growth, China and U.S. sales growth, new highs for DBA and China, and the need to verify the disposal of short-term financial products.
Sources
- Naver Blog original: https://m.blog.naver.com/PostView.naver?blogId=star_of_self&logNo=223552153670
- Butler Works: https://www.butler.works/